Cibus Inc (CBUS) Stock Analysis
Verdict: AVOID
Severe cash burn ($51M annual FCF deficit) and high debt ($268M) expose CBUS to imminent dilution risk despite Trait Machine IP potential.
Investment score: 24/100
Analysis as of
Is Cibus Inc stock worth reviewing? The TradeMates thesis
The TradeMates model views CBUS as a high-risk micro-cap biotechnology stock facing imminent liquidity pressure. With an annual FCF deficit of -$51.17M in 2025 and $9.92M cash at year-end, cash runway is under 3 months without external funding. Despite long-term Trait Machine ag-tech platform IP, financial solvency risks dominate near-term outlook.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Cibus Inc opportunities and risks
What speaks for CBUS
- Commercial scaling of Trait Machine platform
What speaks against CBUS
- Imminent cash depletion and acute liquidity runway risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CBUS | n/a | 28.1x | n/a | 45.7% | -2258.9% | -37.9% |
| BMEA | n/a | 0.0x | n/a | 0.0% | 0.0% | -36.3% |
| VXRT | 3.1x | 0.5x | 1.5x | 100.0% | 15.9% | 29.3% |
| VTVT | n/a | 2.2x | 0.8x | 100.0% | -12.9% | -20.5% |
| INO | n/a | 0.0x | n/a | 0.0% | 0.0% | -93.5% |
| EQ | n/a | 0.0x | n/a | 0.0% | 0.0% | -16.8% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -20.5% |
Frequently asked questions about Cibus Inc (CBUS)
Is CBUS stock a good investment?
The TradeMates model rates Cibus Inc as AVOID with an investment score of 24/100. The TradeMates model views CBUS as a high-risk micro-cap biotechnology stock facing imminent liquidity pressure. With an annual FCF deficit of -$51.17M in 2025 and $9.92M cash at year-end, cash runway is under 3 months without external funding. Despite long-term Trait Machine ag-tech platform IP, financial solvency risks dominate near-term outlook. This is algorithmic model output, not personal investment advice.
Is CBUS stock a buy?
The TradeMates model verdict for CBUS is AVOID with an investment score of 24/100. Treat this as a model signal to review, not a personal buy recommendation.